Globus Medical Company Profile (NYSE:GMED)

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

Globus Medical, Inc. (NYSE:GMED) released its earnings results on Wednesday, August, 2nd. The company reported $0.32 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.30 by $0.02. The company earned $152.39 million during the quarter, compared to the consensus estimate of $150.94 million. Globus Medical had a net margin of 18.12% and a return on equity of 13.99%. The company's revenue was up 10.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.29 EPS. View Globus Medical's Earnings History.

Globus Medical is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Globus Medical.

Globus Medical updated its FY17 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share (EPS) guidance of $1.27 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.27. The company issued revenue guidance of $625 million, compared to the consensus revenue estimate of $625.81 million.

12 brokerages have issued 1-year target prices for Globus Medical's stock. Their forecasts range from $23.00 to $38.00. On average, they expect Globus Medical's stock price to reach $30.71 in the next year. View Analyst Ratings for Globus Medical.

Here are some recent quotes from research analysts about Globus Medical stock:

• 1. According to Zacks Investment Research, "Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company's products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. " (10/4/2017)
• 2. Needham & Company LLC analysts commented, "GMED’s core spine organic growth has slowed though we expect some improvement in 2018 due to sales force enhancements. Its Emerging Technologies business should begin to add to growth in 2018 as well. But even accounting for this, we’re concerned that consensus 2018 estimates may be too high. And we believe that GMED’s earnings growth is going to be mostly driven by revenue growth." (9/26/2017)
• 3. Barclays PLC analysts commented, "ELGX’s 2Q17 sales of $48.6M (-4.7%) came in ahead of our/consensus estimates of $47.6M; higher OUS sales offset lighter US results impacted by sales force attrition and lower AFX2 sales recapture. Ovation growth remained strong. Net loss was better on higher sales, better GM, and lower opex. ELGX lowered FY17 guidance by $9M at the midpoint to $185-190M on lower AFX2 sales recapture and sales force attrition. ELGX expects to begin PMA enrollment for Gen2 Nellix in late 2017/early 2018. We expect a slight uptick in 2H17 sales as AFX2 US softness continues, offset by Ovation US growth. We assume higher growth in ’18 versus ’17 on easier ’17 comps from both AFX manufacturing issues and the narrowed Nellix IFU." (8/3/2017)
• 4. Aegis analysts commented, "GMED reported 4Q16 non-GAAP EPS and revenues of $0.31 and $151.6 million (6.3%/6.5% cc), respectively, with EPS 2 cents short of our and consensus estimates and revenues in line with preliminary reported revenues. Gross margins for the quarter were 74.3%, down from 75.4% in 4Q15 due to one-time accounting adjustments and acquisition-related costs. Despite increasing investments, management maintained strong non-GAAP adjusted EBITDA margins of 37.7% though non-GAAP EPS fell short by 2 cents. During the call management emphasized that sales force issues are now behind them and, most importantly, that they expect to see a return to positive organic US growth in 1Q17. Management believes that this is the inflection point and is re-affirming FY2017 guidance of $625 million in revenues and $1.27 in EPS ' roughly 6.4% organic top-line growth. We believe US approval of its Excelsius GPS robot (expected by mid-year) and build out of its trauma business will provide upside to the business, where management is assuming a modest $10 million in emerging technologies contribution in 2017. We re-iterate our Buy rating and $31 TP." (2/28/2017)

Some companies that are related to Globus Medical include Exact Sciences Corporation (EXAS), Charles River Laboratories International (CRL), Hill-Rom Holdings (HRC), Neurocrine Biosciences (NBIX), United Therapeutics Corporation (UTHR), PRA Health Sciences (PRAH), athenahealth (ATHN), Envision Healthcare Corporation (EVHC), Bio-Techne Corp (TECH), Medidata Solutions (MDSO), HealthSouth Corporation (HLS), Juno Therapeutics (JUNO), ACADIA Pharmaceuticals (ACAD), Masimo Corporation (MASI), PAREXEL International Corporation (PRXL), VWR Corporation (VWR), Valeant Pharmaceuticals International (VRX) and Taro Pharmaceutical Industries (TARO).

Shares of Globus Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Globus Medical stock can currently be purchased for approximately $30.18.